Jasmijn Sleutjes

Erasmus MC | Erasmus MC · Department of Gastroenterology and Hepatology

Background The advantage of early ileocecal resection after Crohn’s disease diagnosis is a matter of debate. This study aims to assess the timing of ileocecal resection on prognosis, after correction for possible confounders. Methods Patients with Crohn's disease with primary ileocecal resection between 2000 and 2019 were included in a retrospecti...

Background Integration of sex and gender into health research is best practice for designing and conducting equitable, rigorous scientific research. Many evidence-based resources exist to support researchers in this endeavour, but such resources often remain underutilized as they are difficult to find, are not publicly accessible, or are specific t...

Aims: Inflammatory bowel disease (IBD) is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). We compared CVD risk factors and 10-years risk in IBD patients to the general population. Methods: In this cross-sectional study consecutive IBD patients ≥45 years were included. History of ASCVD and CVD risk factors (sm...

Background Dyslipidemia may be an important modifiable risk factor contributing to the increased cardiovascular risk in inflammatory bowel disease (IBD). The lipid metabolism is subject to both systemic inflammation and drug therapy; however, it is unclear if this effect is drug-class dependent. Our aim was to assess lipid changes after IBD inducti...

Background Increase in lipid levels associated with the treatment of inflammatory bowel disease (IBD) has previously been reported. However, it is unknown if this effect is similar for all IBD drug classes. Aim To precisely assess the effect of different IBD drug classes on lipid profiles Methods We performed a systematic literature search of ran...

Inflammatory bowel disease (IBD) is associated with an increased risk of cardiovascular disease (CVD). The increased risk of CVD concerns an increased risk of venous thromboembolism (VTE), atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF), at corresponding relative risks of 2.5, 1.2 and 2.0, respectively, as compared with the ge...

Background & Aims Tools for stratification of relapse risk of Crohn’s disease (CD) after anti–tumor necrosis factor (TNF) therapy cessation are needed. We aimed to validate a previously developed prediction model from the diSconTinuation in CrOhn’s disease patients in stable Remission on combined therapy with Immunosuppressants (STORI) trial, and t...

Background Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). Aim To evaluate effectiveness, safety and use of tofacitinib in daily practice. Methods UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Corticosteroid‐free clinical remission (short clinical...